Document is current
Any future updates will be listed below
-
Authors
Fang, Lishan
Ford-Roshon, Dane https://orcid.org/0000-0002-5197-7458
Russo, Max https://orcid.org/0000-0002-3822-6350
O’Brien, Casey
Xiong, Xiaozhe
Gurjao, Carino
Grandclaudon, Maximilien
Raghavan, Srivatsan https://orcid.org/0000-0002-5374-9918
Corsello, Steven M. https://orcid.org/0000-0002-9929-3709
Carr, Steven A.
Udeshi, Namrata D. https://orcid.org/0000-0001-5312-1402
Berstler, James
Sicinska, Ewa
Ng, Kimmie
Giannakis, Marios https://orcid.org/0000-0001-9012-6982
-
Funding
Funding for this research was provided by:
Bayer
Bristol-Myers Squibb
Servier
Janssen Pharmaceuticals
- License Information
-
More Information
Article History
Received: 30 July 2021
Accepted: 18 May 2022
First Online: 8 June 2022
Competing interests
: M.Gi. received research funding from Bristol-Myers Squibb, Merck, Servier and Janssen. S.R. holds equity in Amgen. S.M.C. received research funding from Bayer and Calico Life Sciences. S.A.C. is a member of the scientific advisory boards of Kymera, PTM BioLabs, Seer and PrognomIQ. The remaining authors declare no competing interests.
